Replies to post #19202 on Momenta Pharmaceuticals, Inc. (MNTA)

[dangerM]

Well, I guess the Chinese bid was the only one considered high enough (i.e. other bidders already acknowledged the difficulties of bringing "another" adalimumab biosimilar and offered a much too low / negative premium to development costs)?